CA2718639A1 — Methylphenidate extended release therapeutic drug delivery system
Assigned to FINCHLEY RESEARCH & DEVELOPMENT INC. · Expires 2009-10-01 · 17y expired
What this patent protects
The present invention relates to an extended release therapeutic drug delivery system comprising a controlled release core matrix composition comprising an active pharmaceutical ingredient such as a central nervous system stimulant (e.g., methylphenidate) and a release controllin…
USPTO Abstract
The present invention relates to an extended release therapeutic drug delivery system comprising a controlled release core matrix composition comprising an active pharmaceutical ingredient such as a central nervous system stimulant (e.g., methylphenidate) and a release controlling agent (i.e., HPMC -K4M, HPMC-K I00M CR or HPMC-K 15 M CR) as well as a controlled release coating layer composition covering the core matrix composition, which comprises controlled release polymers such as Eudragit RL 30D. The extended release therapeutic drug delivery system is for use once or twice daily administration. The present invention also relates to processes for manufacturing such an extended release therapeutic drug delivery system.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.